LncRNA FAM66C inhibits pancreatic cancer progression by sponging miR-574-3p

Pancreatic cancer is a highly aggressive cancer type, which ranks in the fourth leading cause for all human malignancies (1), and it is reported that patients with pancreatic cancer are frequently accompanied with poor survival rates owing to its metastasis and limited diagnosis and therapy methods (2-4). Correspondingly, despite that genetic alterations of several paramount molecules has been reported to be associated with progression of pancreatic cancer, for instance, K-Ras (5), INK4a (6), Tp53 (7) and SMAD4 (8), effective drugs targeting them are hardly realized for clinic due to the off-target effects or the drug resistance. Thus, demand to pursue novel diagnosis biomarkers or therapeutic targets for pancreatic cancer patients is pressing Original Article